Approximately eighty percent of the research on the weight loss drug Ozempic has focused on its possible use as a therapy for multiple sclerosis (MS). The University of Nebraska-led study indicated that patients receiving Ozempic as one of fifteen weight reduction medications in the database had a 76% reduced chance of developing multiple sclerosis compared to patients taking the other fourteen pharmaceuticals in the database. Novo Nordisk, the pharmaceutical company behind the treatment, can gain even more financially from the results since the obesity medicines industry is valued at $80 billion this year.
The most recent findings bolster earlier assertions on far-reaching advantages, such as lowering the risk of cardiovascular illness, renal disease, liver issues, and Alzheimer’s. Semaglutide, the generic version of Ozempic, was one of fifteen weight reduction medications that participants in the MS study examined in terms of MS symptoms. Compared to individuals on the other 14 treatments in the database, those using semaglutide had a 76% reduced chance of getting MS, while those using dulaglutide, or Trulicity, had an 83.5 percent lower risk.
Eli Lilly, the pharmaceutical company developing the medicine, has initiated a trial studying the effects of tirzepatide on patients with the prevalent sleep disorder sleep apnea. Mounjaro was administered once weekly to about 500 individuals who participated in the research. The disease is anticipated to improve as a result of the drug-induced weight reduction. Excess fat in the neck region might exacerbate the problem by increasing pressure on the upper airway.
The research is being conducted at a time of great interest in weight reduction therapies, as the prescription of Ozempic and comparable pharmaceuticals is expected to increase by 300 percent from 2019 to 2022. These medications make you feel full for longer periods of time without eating by activating GLP-1 receptors in your brain. Despite this, 117 deaths have been associated with the medications since their distribution, leading some to worry that the dangers are being ignored.
The supposed advantages of the medication are often associated with its capacity to hasten weight loss. While weight reduction is certainly a benefit, other studies have shown that there may be other, more substantial explanations for the many advantages. The MS research examined health records from almost 600,000 people who have used 15 different diet pills since 2003. The University of Nebraska Medical Center provided funding for the study.
